Advertisement

Alternatives to Human Blood Resources

  • P. M. Ness
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 36)

Abstract

The discovery of the acquired immune deficiency syndrome (AIDS) in the 1980’s and its rapid evolution as a major concern for physicians and their patients has lead to many questions about the safety of the blood supply. The attention placed upon AIDS has resulted in new discoveries and technologies to reduce the risk of other transfusion complications such as hepatitis, bacterial contamination, and transfusion-associated graft versus host disease (TA-GvHD). Concerns about blood safety have focused much attention on alternative blood transfusion strategies such as autologous blood, viral inactivation, and artificial blood substitutes. In particular, there has been major interest in the development of alternatives to human blood resources such as blood substitutes. This paper will review the current status of human blood substitutes with particular emphasis upon red cell substitutes. The progress in the development of red cell substitutes will demonstrate that there will be some losses of functionality compared to human red cells, but some product characteristics may result in new therapeutic applications for these products.

Keywords

Sickle Cell Anaemia Acquire Immune Deficiency Syndrome Autologous Blood Oxygen Carrier Allogeneic Blood 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sullivan MT, Wallace EL, Umana WO, Schreiber GB. Trends in the collection and transfusion of blood in the United States, 1987–1997. Transfusion 1999;39:15.Google Scholar
  2. 2.
    Lenny LL, Hurst R, Zhu A, Goldstein J, Goldbraith RA. Multiple-unit and second transfusions of red cells enzymatically converted from group B to group O: report on the end of phase I trials. Transfusion 1995;35:899–902.PubMedCrossRefGoogle Scholar
  3. Consensus conference. Perioperative red blood cell transfusion.JAMA 1988;260: 2700–03.Google Scholar
  4. 4.
    Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ, for the Retrovirus Epidemiology Donor Study. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Klein HG. The prospects for red-cell substitutes. N Engl J Med 2000:342:1666–68.PubMedCrossRefGoogle Scholar
  6. 6.
    Gould SA, Moss GS. Clinical development of human polymerized hemoglobin as a blood substitute. World J Surg 1996;20:200–07.Google Scholar
  7. 7.
    Kaufman R. Clinical development of perfluorocarbon-based red cell substitutes. In Winslow R, Vandegriff K, Intaglietta M eds): Blood Substitutes: Physiologic Basis of Efficacy. New York: Birkhauser; 1995.Google Scholar
  8. 8.
    Keipert PE, Gonzales A, Gomez Cl,. MacDonald VW, Hess JR, Winslow RM. Acute changes in systemic blood pressure and urine output of conscious rats following exchange transfusion with diaspirin-crosslinked hemoglobin solution. Transfusion 1993; 33:701–08.PubMedCrossRefGoogle Scholar
  9. 9.
    Sloan EP, Koenigsberg M. Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999;282:1857–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Winslow RM, Gonzales A, Gonzales ML, et al. Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage mode. J Appl Physiol 1998;85:993–1003.PubMedGoogle Scholar
  11. 11.
    Seghal L.R, Rosen AL, Noud G, et al. Large volume preparation of pyridoxylated hemoglobin with high in vivo P50. J Surg Res 1981:30:14–20.CrossRefGoogle Scholar
  12. 12.
    Ma Z, Monk TG, Goodnough LT, et al. Effect of hemoglobin and Pertlubron-based oxygen carriers on common clinical laboratory tests. Clin Chem 1997;43:1732–37.PubMedGoogle Scholar
  13. 13.
    Gould SA, Moore EE, lloyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 1998;187:113–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Mullon J, Giacoppe G, Clagett C, McCune D, Dillard T. Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N Engl.1 Med 2000;342:1638–43.CrossRefGoogle Scholar
  15. 15.
    LaMuraglia GM,O’Yllara PJ. Baker WIT. et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution.J Vac Surg 2000;31:299–308.CrossRefGoogle Scholar
  16. 16.
    Rottman G, Ness PM. Acute normovolemic hemodilution is a legitimate alternative to allogeneic blood transfusion. Transfusion 1998;38:477–80.PubMedCrossRefGoogle Scholar
  17. 17.
    Triulzi DJ, Gilmor GD, Ness PM, et al. Efficacy of autologous fresh whole blood or platelet-rich plasma in adult cardiac surgery. Transfusion 1995;35:627–34.PubMedCrossRefGoogle Scholar
  18. 18.
    Winslow RM. Red cell substitutes. In: Hoffman R, Benz E.1. Shattil Si. et al, eds. Hematology: basic principles and practice. 3rd edition. Philadelphia: Churchill Livingstone. 2000:2343–48.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2001

Authors and Affiliations

  • P. M. Ness
    • 1
    • 2
  1. 1.Transfusion Medicine Div, Dept Pathology, Johns Hopkins Medical Institutions and Greater Chesapeake and Potomac RegionAmerican Red Cross Blood ServicesBaltimoreUSA
  2. 2.Northfield LaboratoriesEvanstonUSA

Personalised recommendations